Advanced

HAMLET Treatment Delays Bladder Cancer Development.

Mossberg, Anki LU ; Hou, Yuchuan; Svensson, Majlis LU ; Holmqvist, Bo and Svanborg, Catharina LU (2010) In The Journal of urology 183. p.1590-1597
Abstract
PURPOSE: HAMLET is a protein-lipid complex that kills different types of cancer cells. Recently we observed a rapid reduction in human bladder cancer size after intravesical HAMLET treatment. In this study we evaluated the therapeutic effect of HAMLET in the mouse MB49 bladder carcinoma model. MATERIALS AND METHODS: Bladder tumors were established by intravesical injection of MB49 cells into poly L-lysine treated bladders of C57BL/6 mice. Treatment groups received repeat intravesical HAMLET instillations and controls received alpha-lactalbumin or phosphate buffer. Effects of HAMLET on tumor size and putative apoptotic effects were analyzed in bladder tissue sections. Whole body imaging was used to study HAMLET distribution in tumor bearing... (More)
PURPOSE: HAMLET is a protein-lipid complex that kills different types of cancer cells. Recently we observed a rapid reduction in human bladder cancer size after intravesical HAMLET treatment. In this study we evaluated the therapeutic effect of HAMLET in the mouse MB49 bladder carcinoma model. MATERIALS AND METHODS: Bladder tumors were established by intravesical injection of MB49 cells into poly L-lysine treated bladders of C57BL/6 mice. Treatment groups received repeat intravesical HAMLET instillations and controls received alpha-lactalbumin or phosphate buffer. Effects of HAMLET on tumor size and putative apoptotic effects were analyzed in bladder tissue sections. Whole body imaging was used to study HAMLET distribution in tumor bearing mice compared to healthy bladder tissue. RESULTS: HAMLET caused a dose dependent decrease in MB49 cell viability in vitro. Five intravesical HAMLET instillations significantly decreased tumor size and delayed development in vivo compared to controls. TUNEL staining revealed selective apoptotic effects in tumor areas but not in adjacent healthy bladder tissue. On in vivo imaging Alexa-HAMLET was retained for more than 24 hours in the bladder of tumor bearing mice but not in tumor-free bladders or in tumor bearing mice that received Alexa-alpha-lactalbumin. CONCLUSIONS: Results show that HAMLET is active as a tumoricidal agent and suggest that topical HAMLET administration may delay bladder cancer development. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
The Journal of urology
volume
183
pages
1590 - 1597
publisher
Lippincott Williams & Wilkins
external identifiers
  • WOS:000275968200132
  • PMID:20172551
  • Scopus:77949288877
ISSN
1527-3792
DOI
10.1016/j.juro.2009.12.008
language
English
LU publication?
yes
id
f6d451fa-6f5b-457e-afb4-da26ea389f3d (old id 1552460)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20172551?dopt=Abstract
date added to LUP
2010-03-03 14:06:51
date last changed
2016-11-27 04:29:09
@misc{f6d451fa-6f5b-457e-afb4-da26ea389f3d,
  abstract     = {PURPOSE: HAMLET is a protein-lipid complex that kills different types of cancer cells. Recently we observed a rapid reduction in human bladder cancer size after intravesical HAMLET treatment. In this study we evaluated the therapeutic effect of HAMLET in the mouse MB49 bladder carcinoma model. MATERIALS AND METHODS: Bladder tumors were established by intravesical injection of MB49 cells into poly L-lysine treated bladders of C57BL/6 mice. Treatment groups received repeat intravesical HAMLET instillations and controls received alpha-lactalbumin or phosphate buffer. Effects of HAMLET on tumor size and putative apoptotic effects were analyzed in bladder tissue sections. Whole body imaging was used to study HAMLET distribution in tumor bearing mice compared to healthy bladder tissue. RESULTS: HAMLET caused a dose dependent decrease in MB49 cell viability in vitro. Five intravesical HAMLET instillations significantly decreased tumor size and delayed development in vivo compared to controls. TUNEL staining revealed selective apoptotic effects in tumor areas but not in adjacent healthy bladder tissue. On in vivo imaging Alexa-HAMLET was retained for more than 24 hours in the bladder of tumor bearing mice but not in tumor-free bladders or in tumor bearing mice that received Alexa-alpha-lactalbumin. CONCLUSIONS: Results show that HAMLET is active as a tumoricidal agent and suggest that topical HAMLET administration may delay bladder cancer development.},
  author       = {Mossberg, Anki and Hou, Yuchuan and Svensson, Majlis and Holmqvist, Bo and Svanborg, Catharina},
  issn         = {1527-3792},
  language     = {eng},
  pages        = {1590--1597},
  publisher    = {ARRAY(0x91e22c0)},
  series       = {The Journal of urology},
  title        = {HAMLET Treatment Delays Bladder Cancer Development.},
  url          = {http://dx.doi.org/10.1016/j.juro.2009.12.008},
  volume       = {183},
  year         = {2010},
}